52-Week Performance Chart

Powered by FactSet Research Systems Inc

Corporate Actions/Books Closed

More
Apr 10, 2025
Quoin Pharmaceuticals, Ltd. - Books Closed / Open Announcement
Apr 04, 2025
Quoin Pharmaceuticals, Ltd. - Ratio Change and Reverse Split - REVISED
Mar 25, 2025
Quoin Pharmaceuticals, Ltd. - Ratio Change and Reverse Split
Nov 03, 2023
Quoin Pharmaceuticals Ltd - Ratio Change

Capital Raising Events

More
DR Price Date DR Price (USD) US/Non-US/Total DRS US/Non-US/Total DR Capital Raised
Feb 22, 2023 1.00 4,950,000
0
4,950,000
4,950,000
0
4,950,000
Aug 05, 2022 5.00 2,210,000
0
2,210,000
11,050,000
0
11,050,000
Jan 07, 2020 3.00 1,000,000
0
1,000,000
3,000,000
0
3,000,000
Feb 07, 2019 1.50 2,239,000
0
2,239,000
3,358,500
0
3,358,500

Institutional Ownership

TOP INSTITUTIONAL HOLDERS POSITION
Armistice Capital LLC 15,143
Altium Capital Management LLC 8,064
Ikarian Capital LLC 7,857
TOP MUTUAL FUND HOLDERS POSITION

Data provided by FactSet Research Systems Inc.

DR Details

DR Symbol QNRX
CUSIP 74907L409
DR Venue NASDAQ Stock Market
DR ISIN US74907L4095
Ratio DR:ORD 1:35
Local Exchange Not Traded
Underlying ISIN IL0002410186
Country Israel
Effective Date Aug 03, 2016
Depositary BK (Sponsored)
Industry Pharma. & Biotech.
Books Open/Closed Open
Quoin Pharmaceuticals is a biotechnology company that has developed a platform known as ApoGraft that functionally selects stem cells in order to improve the regenerative medicine and stem cell therapies. The Company is conducting two clinical trials of ApoGraft, a Phase I/II clinical trial in Israel and a Phase I clinical study in Washington University. In addition, the Company is in the process of scaling up its product manufacturing capabilities based on its ApoGraft technology. ApoGraft is being tested for clinical use in allogeneic matched and half matched donors Hematopoietic Stem Cells Transplantation for the treatment of hematological malignancies (blood cancers such as leukemia and lymphoma).

Data provided by Mergent, Inc.

Fee Type in US Dollar per ADS Deposit Agreement
Annual Depositary Service up to $0.0500
Cancellation up to $0.0500
Cash Distribution up to $0.0500
Issuance up to $0.0500
Registrar Inspection up to $0.0000
Cash Distribution(Other) up to $0.0500
Rights - Issuance up to $0.0500
Stock Dividend up to $0.0500
Transfer up to $0.0000
Cable Fee per Cancellation $17.5000

Monthly Trading Summary

More
Month Month End DR Close Price DR Trading Volume Avg Day DR Trading Volume
Apr.25 6.77 223,689,070 10,651,860
Mar.25 0.22 11,494,553 547,360
Feb.25 0.31 232,762,616 12,250,664

Powered by FactSet Research Systems Inc.

This information and data is provided for general informational purposes only.  Certain displayed prices may not reflect direct quotes from any market or exchange, but may instead reflect an approximation of price based on a methodology that includes a calculation that includes the price of underlying securities and foreign exchange rate selected for such purpose. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to Terms of Use

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE